First published February 1, 2011 - More info
Original citation: J. Clin. Invest. 2010;120(12):4546–4557. doi:10.1172/JCI43127.
Citation for this corrigendum: J. Clin. Invest. 2011;121(2):821. doi:10.1172/JCI46311.
In the section of Methods titled “Antibodies and flow cytometric analysis,” the antibody clone name for the anti–Tim-3 antibody was given incorrectly. The correct sentences appear below:
Directly conjugated antibodies against the following surface molecules were used: CCR7–PE-Cy7 (clone 3D12), CD27–APC-H7 (clone M-T271), CD45RA-APC (clone HI100), CD69-FITC (clone L78), HLA-DR–PerCP (clone L243), CD45RO–PE-Cy7 (clone UCHL1), CD3–Pacific Blue (clone UCHT1), CD4-V500 (clone RPA-T4), CD8–Alexa Fluor 700 or CD8-PerCP (clone SK1), and PD-1–FITC (clone MIH4), all from BD Biosciences. The PE-conjugated antibody and the blocking antibody for Tim-3 (clone 344823) were obtained from R&D; the blocking antibody gave results that were comparable to those of 1G5 anti–Tim-3 antibody, provided by Vijay Kuchroo (Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA).
The authors regret the error.